Digital Oral Presentation is now published on ECCO website: Here's the conclusion part :-
"IMP761 is the first LAG-3-specific product candidate that can inhibit antigen-specific T-cell–mediated immune responses in vitro and in vivo, for the treatment of auto-immune diseases".
March 6th 2019 - March 9th 2019
DOP Session 1 - Advances in IBD pathophysiology 2019
DOP07 IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases
M. Angin*1, C. Brignone1, F. Triebel1
1Immutep, Orsay, France
Digital Oral Presentation is now published on ECCO website:...
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.020(7.02%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $1.171M | 3.900M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 101067 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 8068 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
